| | Depleted uranium: Sources, Exposure and Health Effects |
| | 2,62 | | MB |
| | 221 | | stron |
| | 6242 | | ID | World Health Organization |
| | 2001 | | rok |
| | Preface |
| | Executive summary |
| | 1 Introduction 1 |
| | 2 Sources and properties of depleted uranium and uranium 3 |
| | 2.1 Uranium 3 |
| | 2.2 Depleted uranium 6 |
| | 2.3 Summary 8 |
| | 3 Uranium in the environment 11 |
| | 3.1 Air 12 |
| | 3.2 Water 13 |
| | 3.3 Soil 15 |
| | 3.4 Mobility of uranium in soil and water 16 |
| | 3.5 Food 18 |
| | 3.6 Other sources in the human diet 19 |
| | 3.6.1 Cooking and serving containers 19 |
| | 3.6.2 Uranium in dust and soil 19 |
| | 3.7 Summary 21 |
| | 4 Industrial, commercial and military uses of uranium 23 |
| | 4.1 Historical uses 23 |
| | 4.2 Current applications 25 |
| | 4.3 Summary 28 |
| | 5 Factors influencing routes of intake and exposure 29 |
| | 5.1 Introduction 29 |
| | 5.2 Exposure via inhalation 30 |
| | 5.3 Exposure via ingestion 32 |
| | 5.3.1 Staple foods 33 |
| | 5.3.2 Drinking water 36 |
| | 5.3.3 Soil and dust 37 |
| | 5.4 Dermal contact 39 |
| | 5.5 Workplace exposure 40 |
| | 5.6 Summary 41 |
| | 6 Case studies and exposure scenarios 43 |
| | 6.1 Case studies 43 |
| | 6.1.1 Potential exposure from air crashes 43 |
| | 6.1.2 Military uses 45 |
| | 6.2 Environmental exposure scenarios 53 |
| | 6.2.1 Soil 53 |
| | 6.2.2 Water 54 |
| | 6.2.3 Plants 55 |
| | 6.2.4 Animals 56 |
| | 6.3 Human exposure scenarios 56 |
| | 6.4 Summary 59 |
| | 7 Behaviour of uranium in the body 61 |
| | 7.1 Introduction 61 |
| | 7.2 Biodistribution and toxico-kinetics 61 |
| | 7.3 Ingestion 62 |
| | 7.4 Inhalation 63 |
| | 7.5 Injury, insult and dermal sorption 64 |
| | 7.6 Excretion and elimination 64 |
| | 7.7 Accumulation 65 |
| | 7.8 Summary 66 |
| | 8 The chemical toxicity of uranium 67 |
| | 8.1 Introduction 67 |
| | 8.2 Toxicity in experimental animals and humans 68 |
| | 8.2.1 Experimental animals 68 |
| | 8.2.2 Implanted depleted uranium fragments 72 |
| | 8.2.3 Dermal absorption 72 |
| | 8.2.4 Humans 73 |
| | 8.3 In-vitro studies 75 |
| | 8.4 Derivation of a tolerable intake for uranium 76 |
| | 8.4.1 Soluble uranium compounds 76 |
| | 8.4.2 Uranium compounds with limited solubility 79 |
| | 8.4.3 Uranium types practically insoluble in water 79 |
| | 8.4.4 Other uranium compounds 79 |
| | 8.5 Uncertainties of chemical risk assessment 79 |
| | 8.6 Summary 80 |
| | 9 Health effects due to the presence of radioactivity 81 |
| | 9.1 Mechanisms and background 81 |
| | 9.2 Dose limits 83 |
| | 9.3 External radiation exposure 84 |
| | 9.4 Internal exposure 85 |
| | 10 Biokinetics for uranium after internal exposure 87 |
| | 10.1 Introduction 87 |
| | 10.2 Inhalation dose coefficients and annual intake limits 87 |
| | 10.3 Biokinetics of Type F, M and S compounds of uranium after inhalation. 90 |
| | 10.3.1 Acute exposure 91 |
| | 10.3.2 Chronic intake 94 |
| | 10.4 Material specific biokinetic behaviour of inhaled uranium oxides 95 |
| | 10.4.1 Acute exposure 97 |
| | 10.4.2 Chronic exposure 101 |
| | 10.5 Ingestion coefficients and annual intake limits for adult members of the public 103 |
| | 10.6 Wound contamination 103 |
| | 10.7 Summary 103 |
| | 11 Monitoring for internal exposure to depleted uranium 105 |
| | 11.1 External monitoring of the chest 105 |
| | 11.2 Urine and faecal monitoring 108 |
| | 11.2.1 Fluorimetry 109 |
| | 11.2.2 Alpha spectrometry 109 |
| | 11.2.3 Mass spectrometry 110 |
| | 11.3 Wound monitoring 111 |
| | 11.4 Monitoring for individuals potentially exposed to depleted uranium aerosols. 112 |
| | 11.5 Monitoring for those with health effects attributed to exposure to depleted uranium 112 |
| | 11.6 Summary 113 |
| | 12 Biokinetics of uranium species from the standpoint of nephrotoxicty 115 |
| | 12.1 Inhalation of uranium. 115 |
| | 12.2 Ingestion of uranium in drinking water and foods 118 |
| | 12.3 Relationship between kidney content and urinary excretion 118 |
| | 12.4 Modelled kidney concentrations resulting from WHO standards. 120 |
| | 12.4.1 Oral consumption at the TI (soluble compounds) 120 |
| | 12.4.2 Ingestion at the WHO drinking water guideline value 120 |
| | 12.4.3 Inhalation at the TI for Type F (soluble) 121 |
| | 12.4.4 Inhalation at the TI for Type M (moderately soluble) compounds 121 |
| | 12.4.5 Inhalation at the TI for Type S (insoluble) compounds 121 |
| | 12.5 Summary 121 |
| | 13 Protective measures, health monitoring, and medical management 123 |
| | 13.1 Background information 123 |
| | 13.1.1 Public exposure 123 |
| | 13.1.2 Occupational exposure 124 |
| | 13.2 Protective measures 124 |
| | 13.2.1 Locality-based protective measures 125 |
| | 13.2.2 Environment-based protective measures 125 |
| | 13.2.3 Medical-based protective measures 125 |
| | 13.2.4 Occupational measures 126 |
| | 13.3 Preventative actions 127 |
| | 13.3.1 Air 127 |
| | 13.3.2 Children 128 |
| | 13.3.3 Concerned individuals 128 |
| | 13.3.4 Contaminated items 128 |
| | 13.3.5 Drinking water 128 |
| | 13.3.6 Exposed skin 128 |
| | 13.3.7 Food 128 |
| | 13.3.8 Impacted areas 128 |
| | 13.3.9 Metal fragments, depleted uranium munitions, scrap metal and souvenirs 128 |
| | 13.4 Environmental monitoring 129 |
| | 13.4.1 Radiation surveys 129 |
| | 13.4.2 Chemical contamination surveys 129 |
| | 13.5 Health assessment 129 |
| | 13.5.1 Medical diagnosis 130 |
| | 13.5.2 Medical monitoring 132 |
| | 13.5.3 Treatment of human contamination 133 |
| | 14 Health standards, guidelines and recommendations 135 |
| | 14.1 Generic 135 |
| | 14.2 Drinking water 137 |
| | 14.3 Food 138 |
| | 14.4 Soil 138 |
| | 14.5 Air 139 |
| | 15 Summary, Conclusions and Research Needs 141 |
| | 15.1 Summary 141 |
| | 15.1 Conclusions 147 |
| | 15.2 Depleted uranium research needs 148 |
| | Annex 1 Process of uranium enrichment process 151 |
| | Annex 2 Radiological dose due to other nuclides 153 |
| | Annex 3 Uranium in the environment, food and reference data 155 |
| | Annex 4 ICRP Biokinetic models 165 |
| | Annex 5 Chemical toxicity of uranium: Occupational exposure standards after inhalation and the |
| | impact of ICRP biokinetic models 175 |